The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design.
Open accessAbstract
Cathepsin D (EC 3.4.23.5) is a lysosomal protease suspected to play important roles in protein catabolism, antigen processing, degenerative diseases, and breast cancer progression. Determination of the crystal structures of cathepsin D and a complex with pepstatin at 2.5 A resolution provides insights into inhibitor binding and lysosomal targeting for this two-chain, N-glycosylated aspartic protease. Comparison with the structures of a complex of pepstatin bound to rhizopuspepsin and with a human renin-inhibitor complex revealed differences in subsite structures and inhibitor-enzyme interactions that are consistent with affinity differences and structure-activity relationships and suggest strategies for fine-tuning the specificity of cathepsin D inhibitors. Mutagenesis studies have identified a phosphotransferase recognition region that is required for oligosaccharide phosphorylation but is 32 A distant from the N-domain glycosylation site at Asn-70. Electron density for the crystal structure of cathepsin D indicated the presence of an N-linked oligosaccharide that extends from Asn-70 toward Lys-203, which is a key component of the phosphotransferase recognition region, and thus provides a structural explanation for how the phosphotransferase can recognize apparently distant sites on the protein surface.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The protein data bank: A computer-based archival file for macromolecular structures
Bernstein, F. C., Koetzle, T. F., Williams, G. J. B., Meyer, E. F., Brice, M. D., Rodgers, J. R., Kennard, O., Shimanouchi, T., & Tasumi, M. (1977) · Journal of Molecular Biology · doi:10.1016/s0022-2836(77)80200-3 · Cited by 8,578
On the size of the active site in proteases. I. Papain
Schechter, I., & Berger, A. (1967) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(67)80055-x · Cited by 5,204
Kornfeld, S., & Mellman, I. (1989) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.05.110189.002411 · Cited by 1,580
LYSOSOMAL ENZYMES AND THEIR RECEPTORS
von Figura, K., & Hasilik, A. (1986) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.55.070186.001123 · Cited by 916
[17] The kinetics of reversible tight-binding inhibition
Williams, J. W., & Morrison, J. F. (1979) · Methods in Enzymology · doi:10.1016/0076-6879(79)63019-7 · Cited by 693
The Structure and Function of the Aspartic Proteinases
Davies, D. R. (1990) · Annual Review of Biophysics and Biophysical Chemistry · doi:10.1146/annurev.bb.19.060190.001201 · Cited by 658
Peters, P. J., Neefjes, J. J., Oorschot, V., Ploegh, H. L., & Geuze, H. J. (1991) · Nature · doi:10.1038/349669a0 · Cited by 657
Metalloproteinases and cancer invasion.
Liotta, L. A., & Stetler‐Stevenson, W. G. (1990) · PubMed · Cited by 397
Guagliardi, L. E., Koppelman, B., Blum, J. S., Marks, M. S., Cresswell, P., & Brodsky, F. M. (1990) · Nature · doi:10.1038/343133a0 · Cited by 372
Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain.
Cataldo, A. M., & Nixon, R. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.10.3861 · Cited by 340
Cited by
Søndergaard, C. R., Olsson, M. H. M., Rostkowski, M., & Jensen, J. H. (2011) · Journal of Chemical Theory and Computation · doi:10.1021/ct200133y · Cited by 1,929
Eldridge, M. D., Murray, C. W., Auton, T. R., Paolini, G. V., & Mee, R. P. (1997) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1007996124545 · Cited by 1,686
Very fast prediction and rationalization of p Ka values for protein–ligand complexes
Bas, D. C., Rogers, D. M., & Jensen, J. H. (2008) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.22102 · Cited by 1,092
Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design
Babine, R. E., & Bender, S. L. (1997) · Chemical Reviews · doi:10.1021/cr960370z · Cited by 892
Protease Inhibitors: Current Status and Future Prospects
Leung, D., Abbenante, G., & Fairlie, D. P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990412m · Cited by 883
Cathepsin D--many functions of one aspartic protease
Benes, P., Vetvicka, V., & Fusek, M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.02.008 · Cited by 572
Multiple diverse ligands binding at a single protein site: A matter of pre‐existing populations
Ma, B., Shatsky, M., Wolfson, H. J., & Nussinov, R. (2002) · Protein Science · doi:10.1110/ps.21302 · Cited by 420
“1990), human cathepsin D (Baldwin et al. 1993), and plasmepsin II (Silva et al.”
BackgroundStructure and Mechanism of the Pepsin-Like Family of Aspartic Peptidases
Dunn, B. M. (2002) · Chemical Reviews · doi:10.1021/cr010167q · Cited by 372
In silico pharmacology for drug discovery: applications to targets and beyond
Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707306 · Cited by 365
Farzan, M., Schnitzler, C. E., Vasilieva, N., Leung, D., & Choe, H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160115697 · Cited by 357
Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis
Liaudet-Coopman, E., Beaujouin, M., Derocq, D., Garcia, M., Glondu-Lassis, M., Laurent-Matha, V., Prébois, C., Rochefort, H., & Vignon, F. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.06.007 · Cited by 351
Extended disordered proteins: targeting function with less scaffold
Gunasekaran, K., Tsai, C.-J., Kumar, S., Zanuy, D., & Nussinov, R. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00003-3 · Cited by 338
Cathepsin D Deficiency Is Associated with a Human Neurodegenerative Disorder
Steinfeld, R., Reinhardt, K., Schreiber, K., Hillebrand, M., Kraetzner, R., Brück, W., Saftig, P., & Gärtner, J. (2006) · The American Journal of Human Genetics · doi:10.1086/504159 · Cited by 302
Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum.
Silva, A. M., Lee, A. Y., Gulnik, S. V., Maier, P., Collins, J., Bhat, T. N., Collins, P. J., Cachau, R. E., Luker, K. E., Gluzman, I. Y., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10034 · Cited by 270
Self-citationRoca, F. J., Whitworth, L. J., Redmond, S., Jones, A. A., & Ramakrishnan, L. (2019) · Cell · doi:10.1016/j.cell.2019.08.004 · Cited by 233
“We inhibited cathepsins B and D, respectively, using the cysteine cathepsin inhibitor E64d and the aspartyl cathepsin inhibitor pepstatin A (Baldwin et al., 1993; Berg et al., 2016).”
MethodRudenko, G., Bonten, E., d'Azzo, A., & GJ Hol, W. (1995) · Structure · doi:10.1016/s0969-2126(01)00260-x · Cited by 97
Pearson, M. S., Bethony, J. M., Pickering, D. A., de Oliveira, L. M., Jariwala, A., Santiago, H., Miles, A. P., Zhan, B., Jiang, D., Ranjit, N., et al. (2009) · The FASEB Journal · doi:10.1096/fj.09-131433 · Cited by 88
“We showed that the recombinant mutagenized protein retained the same fold as Na-APR-1wt, and although it was no longer catalytically active, Na-APR-1mut bound to pepstatin A, which requires an intimate and complex association between enzyme and inhibitor (31).”
BackgroundLai, C.-M., Robertson, T., Papadimitriou, J., Shen, W.-Y., Daw, N., Constable, I. J., & Rakoczy, P. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0195 · Cited by 5
Metadata
- Authors
- Baldwin, E. T., Bhat, T. N., Gulnik, S., Hosur, M. V., Sowder, R. C., Cachau, R. E., Collins, J., Silva, A. M., & Erickson, J. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1993-07-15
- Volume
- 90
- Issue
- 14
- Pages
- 6796-6800
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2164231548
- Cited by
- 280
- References
- 27
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.